Nontargeted Emergency Department HCV Screening Delivers the Strongest Economic Return
Economic modeling tied to the DETECT Hep C trial points to a clear result: nontargeted hepatitis C virus screening in emergency departments produced the best balance of clinical benefit and cost in the base case analysis. Using a simulated cohort of 500 million individuals and a lifetime horizon, the strategy outperformed both targeted screening and no emergency department screening on infection cure, quality-adjusted survival, and incremental cost-effectiveness.
The analysis used the Hepatitis C Cost-Effectiveness model from a health sector perspective and drew on data from emergency departments at Denver Health Medical Center, Johns Hopkins Hospital, and the University of Mississippi Medical Center. The three strategies compared were no emergency department HCV screening, targeted screening, and nontargeted screening. Future costs and benefits were discounted at 3% annually, and an incremental cost-effectiveness ratio below $100,000 per QALY gained defined cost-effectiveness.
In the base case, nontargeted screening cured 65.89% of infections, generated a discounted cost of $214,465, and yielded 15.8723 discounted QALYs. Its ICER was $12,820 per QALY gained. Those numbers matter because they place the intervention far below the accepted threshold, leaving a wide margin for economic value even when the downstream benefits appear small at the population level.
Tiny Differences at the Population Level Still Translate Into Real Clinical Value
The comparison group results were close on the surface, but the economic model still separated them. No emergency department screening cured 65.60% of infections, yielded 15.8717 QALYs, and cost $214,467. Targeted screening cured 65.88% of infections, yielded 15.8721 QALYs, and cost $214,462. The spread in absolute outcomes was narrow, yet the model still favored nontargeted screening because even small gains in identifying chronic HCV earlier can avert cirrhosis, decompensated liver disease, hepatocellular carcinoma, and transplant-related costs over a lifetime.
A one-sentence clinical reality sits underneath those estimates: emergency departments reach people who otherwise never enter screening pathways.
That access point is the biological and operational reason the intervention performs well. HCV often smolders silently for years, and once treatment is linked after detection, viral cure interrupts the cascade that drives progressive hepatic injury. In that sense, screening is not just a diagnostic exercise; it is the gateway to preventing irreversible organ damage.
The model also explains why the advantages look modest in aggregate. More than 90% of people screened did not have HCV, so most tests did not lead to a cure. Even so, the benefit was concentrated in the subgroup living with infection, where earlier diagnosis, linkage to care, and antiviral treatment shift the long-term disease trajectory in a meaningful way.
Why the Emergency Department Works as a Screening Site
The emergency department remains one of the few places where high-risk and under-screened adults can be reached without requiring prior engagement in primary care. That is especially relevant for HCV, which is often concentrated in populations facing fragmented access to outpatient services, substance use, unstable housing, or repeated acute-care use. In that setting, a nontargeted approach avoids the blind spots created by risk-based eligibility rules, which can miss patients whose histories are incomplete, stigmatized, or simply not captured.
The simulated cohort had a mean age of 46.3 years and was 52.88% male, reflecting a broad adult emergency department population rather than a narrowly selected specialty clinic sample. The scale of the cohort, 500 million individuals, signals that the investigators were asking a systems question rather than a single-center operational question: if emergency departments adopt routine HCV screening, does the policy justify itself across a lifetime of outcomes and costs?
The answer from this model was yes. Routine nontargeted screening generated the strongest cost-effectiveness profile, and the gain was large enough to stand out even when the absolute differences in QALYs and cure rates were small.
What the ICER Means for Public Health Policy
An ICER of $12,820 per QALY gained sits in a range that health systems and payers would generally view as highly favorable. For clinicians and administrators, the more practical implication is that the intervention does not require dramatic benefit to justify adoption; it requires dependable linkage between the screening event and treatment access. Without that handoff, the downstream economic and clinical gains would erode quickly.
The economic framework here also strengthens the argument for HCV elimination strategies that extend beyond the traditional outpatient setting. Emergency departments are not ideal environments for longitudinal prevention, but they are efficient access points for case finding. Once HCV is identified, modern direct-acting antiviral therapy can cure infection and prevent the complications that drive most lifetime cost.
The Decision Still Depends on Execution at the Bedside
The model compared three screening strategies, not the many operational variations that real hospitals must manage. Staffing, reflex testing workflows, linkage-to-care pathways, and payer mix were not the headline variables in the abstract, yet they determine whether cost-effective screening remains workable outside a model. Real-world implementation will rise or fall on whether patients who test positive can move quickly from the emergency department into confirmatory testing and treatment.
The findings also leave room for local adaptation. Institutions with different HCV prevalence, different follow-up infrastructure, or different testing costs may not reproduce the exact ICER, even if the overall direction remains favorable. Economic value in this context is not abstract; it depends on how well screening is embedded into a functioning care pathway.
For now, the modeled evidence supports routine nontargeted emergency department screening as a high-value approach to HCV detection. The remaining challenge is not whether the strategy can work on paper, but whether emergency departments can sustain the diagnostic and treatment pathways needed to convert screening into cure.